BMS's High Court review of NICE abatacept guidance dismissed
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's application to launch a judicial review of the consultation process used by NICE when it appraised the cost effectiveness of its rheumatoid arthritis therapy Orencia (abatacept) has been dismissed by the UK High Court.